Increased cell proliferation and contractility of prostate in insulin resistant rats: Linking hyperinsulinemia with benign prostate hyperplasia

Prostate

Volumn 70, Issue 1, 2010, Pages 79-89

  Vikram, A ^a   Jena, G B ^a   Ramarao, P ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

High fat diet; Hyperinsulinemia; Insulin resistance; Pioglitazone; Prostate; Streptozotocin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; STREPTOZOCIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL HYPERPLASIA; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; GLUCOSE TOLERANCE TEST; HYPERINSULINEMIA; HYPOINSULINEMIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LIPID DIET; METABOLIC SYNDROME X; MUSCLE CONTRACTILITY; MUSCLE ISOMETRIC CONTRACTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; RISK FACTOR;

ANIMALS; CELL PROLIFERATION; DIETARY FATS; HYPERINSULINISM; INSULIN RESISTANCE; MALE; PROSTATE; PROSTATIC HYPERPLASIA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 72849125103     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21041     Document Type: Article

References (43)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132: 474-479. (Pubitemid 14026148)
2. Thiyagarajan M, Kaul CL, Ramarao P. Enhancement of alpha-adrenoceptor- mediated responses in prostate of testosterone-treated rat. Eur J Pharmacol 2002;453:335-344. (Pubitemid 35223527)
3. Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 2004;6 (Suppl 9):S3-S10.
4. Montie JE, Pienta KJ. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology 1994;43:892-899. (Pubitemid 24174489)
5. Sanda MG, Beaty TH, Stutzman RE, Childs B, Walsh PC. Genetic susceptibility of benign prostatic hyperplasia. J Urol 1994;152: 115-119. (Pubitemid 24175715)
6. Bravi F, Bosetti C, Dal Maso L, Talamini R, Montella M, Negri E, Ramazzotti V, Franceschi S, La Vecchia C. Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia. Urology 2006;67:1205-1211. (Pubitemid 43818096)
7. Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular, and molecular control of prostatic development. Dev Biol 2003;253:165-174. (Pubitemid 36259879)
8. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyper-insulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006;370:89-93. (Pubitemid 44080171)
9. Hannah JS, Howard BV. Dietary fats, insulin resistance, and diabetes. J Cardiovasc Risk 1994;1:31-37.
10. Issa MM, Regan TS. Medical therapy for benign prostatic hyperplasia-present and future impact. Am J Manag Care 2007;13 (Suppl 1):S4-S9.
11. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39: 151-158. (Pubitemid 32171181)
12. Hammarsten J, Damber JE, Karlsson M, Knutson T, Ljunggren O, Ohlsson C, Peeker R, Smith U, Mellstrom D. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2009;12:160-165.
13. Escobar EL, Gomes-Marcondes MC, Carvalho HF. Dietary fatty acid quality affects AR and PPARgamma levels and prostate growth. Prostate 2009;69:548-558.
14. Vikram A, Tripathi DN, Ramarao P, Jena GB. Intervention of D-glucose ameliorates the toxicity of streptozotocin in accessory sex organs of rat. Toxicol Appl Pharmacol 2008;226:84-93. (Pubitemid 350235584)
15. Yono M, Pouresmail M, Takahashi W, Flanagan JF, Weiss RM, Latifpour J. Effect of insulin treatment on tissue size of the genitourinary tract in BB rats with spontaneously developed and streptozotocin-induced diabetes. Naunyn Schmiedebergs Arch Pharmacol 2005;372:251-255. (Pubitemid 41668755)
16. Kaufman LN, Peterson MM, Smith SM. Hypertension and sympathetic hyperactivity induced in rats by high-fat or glucose diets. Am J Physiol 1991;260:E95-E100.
17. Young JB. Effect of experimental hyperinsulinemia on sympathetic nervous systemactivity in the rat. Life Sci 1988;43:193-200.
18. Srinivasan K, Patole PS, Kaul CL, Ramarao P. Reversal of glucose intolerance by pioglitazone in high fat diet-fed rats. Methods Find Exp Clin Pharmacol 2004;26:327-333. (Pubitemid 38954807)
19. Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, Sharpless NE. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006;443:453-457. (Pubitemid 44477281)
20. Furie K, Inzucchi SE. Diabetes mellitus, insulin resistance, hyperglycemia, and stroke. Curr Neurol Neurosci Rep 2008; 8:12-19. (Pubitemid 351166410)
21. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, Zhang C, Niu Y, Tsai MY, Chang C. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci USA 2007;104:12679-12684. (Pubitemid 47255214)
22. Schwartz JH, Young JB, Landsberg L. Effect of dietary fat on sympathetic nervous system activity in the rat. J Clin Invest 1983;72:361-370.
23. Landsberg L, Young JB. Insulin-mediated glucose metabolism in the relationship between dietary intake and sympathetic nervous system activity. Int J Obes 1985;9 (Suppl 2):63-68. (Pubitemid 16177130)
24. Rahman NU, Phonsombat S, Bochinski D, Carrion RE, Nunes L, Lue TF.Ananimal model to study lower urinary tract symptoms and erectile dysfunction: The hyperlipidaemic rat. BJU Int 2007;100:658-663. (Pubitemid 47205488)
25. Silva J, Pinto R, Carvallho T, Coelho A, Avelino A, Dinis P, Cruz F. Mechanisms of prostate atrophy after glandular botulinum neurotoxin type A injection: An experimental study in the rat. Eur Urol 2009;56:134-141.
26. Golomb E, Rosenzweig N, Eilam R, Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 2000;21:58-64. (Pubitemid 30069082)
27. Sunano S, Sasaki F. Elevation of spontaneous tone and effects of antihypertensive treatments in arterial smooth muscle of spontaneously hypertensive rats. J Smooth Muscle Res 1993;29: 111-130. (Pubitemid 24043553)
28. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999;104:447-457. (Pubitemid 29534329)
29. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002;277:1794-1799. (Pubitemid 34968751)
30. Wang LM, Keegan A, Frankel M, Paul WE, Pierce JH. Signal transduction through the IL-4 and insulin receptor families. Stem Cells 1995;13:360-368.
31. White MF, Maron R, Kahn CR. Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 1985;318:183-186. (Pubitemid 16192587)
32. White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994;269:1-4.
33. Simon MA, Dodson GS, Rubin GM. An SH3-SH2-SH3 protein is required for p21Ras1 activation and binds to sevenless and Sos proteins in vitro. Cell 1993;73:169-177. (Pubitemid 23115458)
34. Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, Bar-Sagi D, Margolis B, Schlessinger J. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 1993;363:85-88. (Pubitemid 23144968)
35. Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, Daly R, Myers MJ Jr, Backer JM, Ullrich A, White MF, Vikram A, Jena GB, Ramarao P. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: Implications for insulin control of ras signalling. EMBO J 1993;12:1929-1936. (Pubitemid 23157709)
36. Pronk GJ, Medema RH, Burgering BM, Clark R, McCormick F, Bos JL. Interaction between the p21ras GTPase activating protein and the insulin receptor. J Biol Chem 1992;267:24058-24063. (Pubitemid 23088225)
37. Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, Ullrich A, Skolnik EY, Bar-Sagi D, Schlessinger J. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992;70:431-442.
38. Crews CM, Erikson RL. Extracellular signals and reversible protein phosphorylation: What to Mek of it all. Cell 1993;74:215-217. (Pubitemid 223013587)
39. Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 1999;151:65-77.
40. Cruzalegui FH, Cano E, Treisman R. ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry. Oncogene 1999;18:7948-7957. (Pubitemid 30050555)
41. O'Neill E, Kolch W. Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer 2004;90:283-288. (Pubitemid 38250615)
42. Shaul YD, Seger R. The MEK/ERK cascade: From signaling specificity to diverse functions. Biochim Biophys Acta 2007;1773:1213-1226. (Pubitemid 47125968)
43. Shen D, Deng C, Zhang M. Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgrad Med J 2007;83:414-419. (Pubitemid 46960828)